EVA1C

Across TCGA pan-cancer cohorts, EVA1C Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated EVA1C data layer compared with 26 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher EVA1C Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated EVA1C expression acts as an unfavorable survival marker, although some lineages such as LUSC show a favorable association.

HNSC, STAD, and UCEC are the cancer types where EVA1C Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	IV	0.051	0.708	<.001	48	view →
STAD	OS	Median	All	0.152	0.567	.010	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	DFS	Median	All	0.167	0.555	.039	6	view →
COAD	DFS	Median	All	0.208	0.696	.041	3	view →
LUSC	DFS	Median	All	1.000	0.367	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

EVA1C–HNSC (OS)

Open the HNSC breakdown →